- Home
- FTDR vs XENE Comparison
FTDR vs XENE Comparison
Compare FTDR & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- XENE
- Stock Information
- Founded
- FTDR 1971
- XENE 1996
- Country
- FTDR United States
- XENE Canada
- Employees
- FTDR N/A
- XENE N/A
- Industry
- FTDR Diversified Commercial Services
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- XENE Health Care
- Exchange
- FTDR Nasdaq
- XENE Nasdaq
- Market Cap
- FTDR 2.9B
- XENE 2.5B
- IPO Year
- FTDR 2018
- XENE 2014
- Fundamental
- Price
- FTDR $53.47
- XENE $35.54
- Analyst Decision
- FTDR Hold
- XENE Strong Buy
- Analyst Count
- FTDR 5
- XENE 9
- Target Price
- FTDR $46.50
- XENE $56.22
- AVG Volume (30 Days)
- FTDR 917.6K
- XENE 862.0K
- Earning Date
- FTDR 05-01-2025
- XENE 05-12-2025
- Dividend Yield
- FTDR N/A
- XENE N/A
- EPS Growth
- FTDR 34.69
- XENE N/A
- EPS
- FTDR 3.08
- XENE N/A
- Revenue
- FTDR $1,891,000,000.00
- XENE N/A
- Revenue This Year
- FTDR $11.77
- XENE N/A
- Revenue Next Year
- FTDR $6.46
- XENE $1,553.36
- P/E Ratio
- FTDR $17.41
- XENE N/A
- Revenue Growth
- FTDR 5.58
- XENE N/A
- 52 Week Low
- FTDR $32.95
- XENE $26.74
- 52 Week High
- FTDR $63.49
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- FTDR 81.82
- XENE 49.08
- Support Level
- FTDR $40.11
- XENE $37.46
- Resistance Level
- FTDR $53.97
- XENE $39.01
- Average True Range (ATR)
- FTDR 1.71
- XENE 1.68
- MACD
- FTDR 1.59
- XENE -0.14
- Stochastic Oscillator
- FTDR 96.71
- XENE 48.59
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.